Impact of Small Molecules Immunosuppressants on P-glycoprotein Activity and T-cell Function

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 3, 2012, Pages 407-419

  Llaudó, Inés ^a   Cassis, Linda ^a   Torras, Joan ^a   Bestard, Oriol ^a   Franquesa, Marcella ^a   Cruzado, Josep M ^a   Cerezo, Gema ^a   Castaño, Esther ^b   Pètriz, Jordi ^c   Herrero Fresneda, Immaculada ^a   Grinyó, Josep M ^a   Lloberas, Núria ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; RHODAMINE 123; TACROLIMUS; VALSPODAR;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL ISOLATION; CELL KINETICS; CELL POPULATION; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG INHIBITION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MONOTHERAPY; NORMAL HUMAN; PROTEIN FUNCTION; T LYMPHOCYTE;

EID: 84865103197     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3g30b     Document Type: Article

References (36)

1. Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol, 2004; 60(2):97-102.
2. Lucia MB, Rutella S, Leone G, Vella S, Cauda R. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr, 2001; 27(4):321-330.
3. Rao US, Scarborough GA. Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol, 1994; 45(4):773-776.
4. Wang Y, Hao D, Stein WD, Yang L. A kinetic study of Rhodamine123 pumping by P-glycoprotein. Biochim Biophys Acta, 2006; 1758(10):1671-1676.
5. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett, 2006; 580(4):998-1009.
6. Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. Specific MDR1. P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol, 2001; 166(4):2451-2459.
7. Shirasaka Y, Onishi Y, Sakurai A, Nakagawa H, Ishikawa T, Yamashita S. Evaluation of human P-glycoprotein (MDR1/ABCB1) ATPase activity assay method by comparing with in vitro transport measurements: Michaelis-Menten kinetic analysis to estimate the affinity of P-glycoprotein to drugs. Biol Pharm Bull, 2006; 29(12):2465-2471.
8. Grude P, Boleslawski E, Conti F, Chouzenoux S, Calmus Y. MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation. Transplantation, 2002; 73(11):1824-1828.
9. Meaden ER, Hoggard PG, Khoo SH, Back DJ. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods, 2002; 262(1-2):159-165.
10. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol, 1997; 40 Suppl:S3-8.
11. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem, 1993; 62:385-427.
12. Pendse SS, Behjati S, Schatton T, Izawa A, Sayegh MH, Frank MH. P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation. Am J Transplant, 2006; 6(12):2884-2893.
13. van de Ven R, de Jong MC, Reurs AW, Schoonderwoerd AJ, Jansen G, Hooijberg JH, Scheffer GL, de Gruijl TD, Scheper RJ. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol, 2006; 176(9):5191-5198.
14. Donnenberg VS, Burckart GJ, Griffith BP, Jain AB, Zeevi A, Berg AD. P-glycoprotein (P-gp) is upregulated in peripheral T-cell subsets from solid organ transplant recipients. J Clin Pharmacol, 2001; 41(12):1271-1279.
15. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant, 2004; 4(9):1514-1522.
16. del Moral RG, Andujar M, Ramirez C, Gomez-Morales M, Masseroli M, Aguilar M, Olmo A, Arrebola F, Guillen M, Garcia-Chicano MJ, Nogales FF, O'Valle F. Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits. Am J Pathol, 1997; 51(6):1705-1714.
17. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Negre E, Burke JT, Groth CG. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant, 2002; 2(5):436-442.
18. Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Meria P, Beaune P, Legendre C, Thervet E. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int, 2006; 70(6):1019-1025.
19. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs, 2003; 63(12):1247-1297.
20. Heidecke CD, Nicolaus C, Stadler J, Florack G, Bollschweiler E, Holscher M. Measurement of cyclosporine bioactivity in serum of renal transplant recipients: development and comparison with RIA. Transplant Proc, 1987; 19(1 Pt 2):1734-1736.
21. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation, 1985; 40(5):457-476.
22. Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC, Kahan BD. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol, 2001; 12(5):1059-1071.
23. Lloberas N, Torras J, Alperovich G, Cruzado JM, Gimenez-Bonafe P, Herrero-Fresneda I, Franquesa M, Rama I, Grinyo JM. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant, 2008; 23(10):3111-3119.
24. Chiva-Blanch G, Gimenez-Bonafe P, Llaudo I, Torras J, Cruzado JM, Petriz J, Castano E, Franquesa M, Herrero-Fresneda I, Tortosa A, Rama I, Bestard O, Grinyo JM and Lloberas N. Different storing and processing conditions of human lymphocytes do not alter P-glycoprotein rhodamine 123 efflux. J Pharm Pharm Sci, 2009; 12(3):357-366.
25. Pawarode A, Shukla S, Minderman H, Fricke SM, Pinder EM, O'Loughlin KL, Ambudkar SV, Baer MR. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother Pharmacol, 2007; 60(2):179-188.
26. Parasrampuria DA, Lantz MV, Birnbaum JL, Vincenti FG, Benet LZ. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J Clin Pharmacol, 2002; 42(3):304-311.
27. Donnenberg VS, Wilson JW, Burckart GJ, Zeevi A, Iacono A, Donnenberg AD. Measurement of basal, substrate induced and total P-glycoprotein activity in bronchoalveolar lavage T-cell subsets. Cytometry A, 2004; 57(2):75-85.
28. Chen JC, Chang ML, Muench MO. A kinetic study of the murine mixed lymphocyte reaction by 5,6-carboxyfluorescein diacetate succinimidyl ester labeling. J Immunol Methods, 2003; 279(1-2):123-133.
29. Pendse S, Sayegh MH, Frank MH. P-glycoprotein- -a novel therapeutic target for immunomodulation in clinical transplantation and autoimmunity?. Curr Drug Targets, 2003; 4(6):469-476.
30. Donnenberg VS, Burckart GJ, Zeevi A, Griffith BP, Iacono A, McCurry KR, Wilson JW, Donnenberg AD. P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection. ransplantation, 2004; 77(11):1699-1706.
31. Parasrampuria DA, Lantz MV, Benet LZ. A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function. Pharm Res, 2001; 18(1):39-44.
32. Demur C, Muller C, Cassar G, Bousquet C, Laroche M, Laurent G. Acute myeloid leukemia cells with low P-glycoprotein expression and high rhodamine 123 efflux capacity display high clonogenicity. Leukemia, 1998; 12(2):192-199.
33. Gupta S, Kim CH, Tsuruo T, Gollapudi S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol, 1992; 12(6):451-458.
34. Singh D, Alexander J, Owen A, Rustom R, Bone M, Hammad A, Roberts N, Park K, Pirmohamed M. Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. Transplantation, 2004; 77(4):557-561.
35. Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann JF, Kassaee A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med, 2004; 10(1):87-92.
36. Wang H, Hosiawa KA, Min W, Yang J, Zhang X, Garcia B, Ichim TE, Zhou D, Lian D, Kelvin DJ, Zhong R. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol, 2003;171(7):3823-3836.